Susan Hutchinson, AAN 2021: Rimegepant for the Prevention and Treatment of Migraine
It was a great pleasure to catch up with Susan Hutchinson (Orange County Migraine & Headache Center, Irvine, CA, USA) to discuss her recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors, for the prevention and treatment of migraine.
The abstract entitled: ‘Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What are the unmet needs in the treatment of migraine in adults with cardiovascular risk factors? (0:13)
- Could you give us a brief overview of the clinical development of small molecule CGRP receptor antagonists for migraine prevention and treatment? (1:01)
- Could you please describe your recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors? (1:40)
- What were the findings of this study and what are their implications for clinical practice? (3:32)
- What does the future migraine treatment landscape look like? (4:46)
Disclosures: In the past two years, Susan Hutchinson has served as a consultant/advisory board member for Alder/Lundbeck, Allergan/AbbVie, Amgen, Biohaven, Currax, electroCore, Impel, Lilly, Novartis, Teva, Theranica, Upsher-Smith; and is on the speaker’s bureau for AbbVie, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Novartis, Teva, Theranica and Upsher-Smith.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]
Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]
Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!